

中文題目：直接作用抗病毒藥物造成慢性 C 型肝炎患者引起的黃疸

英文題目：Jaundice in a chronic hepatitis C patient treated with direct-acting antiviral agents: a case report

作者：許博堯<sup>1</sup>，黃志富<sup>1,2</sup>，葉明倫<sup>1,2</sup>，戴嘉言<sup>1,2,3,4</sup>，余明隆<sup>1,5,6</sup>，莊萬龍<sup>1,2</sup>

服務單位：

<sup>1</sup>高雄醫學大學附設醫院肝膽胰內科

<sup>2</sup>高雄醫學大學醫學院

<sup>3</sup>高雄醫學大學附設醫院職業醫學科

<sup>4</sup>高雄醫學大學附設醫院預防醫學科

<sup>5</sup>國立中山大學生物醫學研究所

<sup>6</sup>麻州總醫院消化科肝病中心

**摘要：**

Direct-acting antiviral agents (DAAs) has become the major therapy for chronic hepatitis C (CHC) in recent years. However, hepatitis B virus (HBV) reactivation (HBVr) remains an important issue among patients with HBV/HCV co-infection when receiving DAAs for their CHC. The severity of HBVr induced hepatitis may range from mild to severe form of liver injury. We present a rare case of HBVr leading to decompensated state and jaundice in a 72-year-old woman during DAA treatment. His decompensated state subsequent to HBVr fortunately improved after initiating oral antiviral for HBV. Our case highlights the importance of pretreatment evaluation of HBV, monitoring potential HBVr, and the initiation of HBV antiviral therapy among those HBV/HCV co-infection patients.